Susan Wellborn
Family · Long Beach, CANPI 1578699484
Payments from drug & device makers
Across 185 payments — averaging $42.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$6K
- Gilead$999
- Johnson & Johnson$304
- EMD Serono, Inc.$170
- Napo Pharmaceuticals Inc$155
- AbbVie$154
- plus $287 from 5 others
What the payments were for
- Consulting fees$3,60046%
- Speaking & faculty fees$330%
- Travel & lodging$5197%
- Food & beverage$3,73847%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 79 | $5,831 |
| Gilead | 49 | $999 |
| Johnson & Johnson(2 entities) | 19 | $304 |
| EMD Serono, Inc. | 7 | $170 |
| Napo Pharmaceuticals Inc | 10 | $155 |
| AbbVie | 7 | $154 |
| Theratechnologies Inc. | 6 | $98 |
| Merck | 4 | $85 |
| GSK | 2 | $52 |
| Medtronic | 1 | $31 |
| Exact Sciences | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DOVATO$123
How this compares
$7,901 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 57 | $215,987 |
| CabenuvaCabotegravir/Rilpivirine | 22 | $127,233 |
| DovatoDolutegravir Sodium/Lamivudine | 34 | $99,597 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 12 | $55,126 |
| TivicayDolutegravir Sodium | 26 | $54,589 |
| PrezcobixDarunavir/Cobicistat | 18 | $40,594 |
| Atazanavir Sulfate | 11 | $2,125 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $973 |
| Testosterone Cypionate | 17 | $503 |
| Gabapentin | 32 | $359 |
| Atorvastatin Calcium | 53 | $341 |
| Tamsulosin Hcl | 35 | $243 |
| Trazodone Hcl | 27 | $232 |
| Rosuvastatin Calcium | 32 | $176 |
| Ibuprofen | 14 | $125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyCabenuva, Dovato, Tivicay | $5,831 | $281,42082 claims |
| GileadBiktarvy | $999 | $215,98757 claims |
| Johnson & JohnsonPrezcobix | $304 | $40,59418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Long Beach
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.